<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05010603</url>
  </required_header>
  <id_info>
    <org_study_id>AAAP0479</org_study_id>
    <secondary_id>1U24AG056270</secondary_id>
    <nct_id>NCT05010603</nct_id>
  </id_info>
  <brief_title>Late Onset Alzheimer's Disease</brief_title>
  <acronym>LOAD</acronym>
  <official_title>Late Onset Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease&#xD;
      (AD) risk. The investigators are looking for families and/or individuals (affected or&#xD;
      unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a&#xD;
      family history of AD and willing to participate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to focus on the genetic influences on Alzheimer's disease (AD)&#xD;
      risk. Specifically, the investigators hypothesize that one or more genes, other than the&#xD;
      previously identified susceptibility gene apolipoprotein-E (APOE), or the 3 genes associated&#xD;
      with early-onset familial AD, presenilin-1 (PS-1), presenilin-2 (PS-2) or B-amyloid precursor&#xD;
      protein (APP), increase the risk of AD in families with multiple individuals affected with&#xD;
      AD. The investigators propose to test this hypothesis by performing genetic linkage analysis&#xD;
      in order to detect the chromosomal location of genes that may increase the risk of&#xD;
      Alzheimer's disease. In addition, the investigators will study genes known to increase the&#xD;
      risk of Alzheimer's disease and other related disorders such as early onset AD, Pick disease,&#xD;
      corticobasal degeneration, progressive supranuclear palsy, and familial frontotemporal&#xD;
      dementia with parkinsonism and Lewy Body Dementia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2016</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of genes identified to be associated with the risk of AD</measure>
    <time_frame>5 years</time_frame>
    <description>Genetic Linkage Analysis to Identify Genes Associated with the risk of Alzheimer's Disease: Identification of genes by performing genetic linkage analysis, in order to detect the chromosomal location of genes that may increase the risk of Alzheimer's disease.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Families with a history of Alzheimer's Disease</arm_group_label>
    <description>Families with two or more family members affected with Alzheimer's Disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Un-related, non-demented controls</arm_group_label>
    <description>Un-related, non-demented healthy controls over age 55</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Individuals with Dementia (Alzheimer's Disease)</arm_group_label>
    <description>Individuals with dementia over the age of 65</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Blood Draw</intervention_name>
    <description>Collection of blood samples for genetic testing</description>
    <arm_group_label>Families with a history of Alzheimer's Disease</arm_group_label>
    <arm_group_label>Individuals with Dementia (Alzheimer's Disease)</arm_group_label>
    <arm_group_label>Un-related, non-demented controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test</intervention_name>
    <description>Memory Test</description>
    <arm_group_label>Families with a history of Alzheimer's Disease</arm_group_label>
    <arm_group_label>Individuals with Dementia (Alzheimer's Disease)</arm_group_label>
    <arm_group_label>Un-related, non-demented controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and samples from autopsy/brain tissue.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The investigators intend to recruit individuals from: 1) community-based studies; 2) the&#xD;
        Alzheimer's Disease Research Center Memory Disorders Center; 3) the private offices of the&#xD;
        study neurologists; 4) public recruitment; 5) referrals from the Alzheimer's Association;&#xD;
        6) referrals from the NCRAD; 7)previously unidentified members of existing families not&#xD;
        previously recruited. The investigators will also use advertisements such as radio,&#xD;
        television and newspapers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Established diagnosis of definite or probable AD or have a diagnosis of a related&#xD;
             neurodegenerative disorder such as Frontotemporal Dementia (FTD) or Lewy Body Dementia&#xD;
             (LBD) (will also recruit sporadic FTD and LBD) cases.&#xD;
&#xD;
          -  a living sibling with probable or possible AD;&#xD;
&#xD;
          -  a third living relative affected with AD (onset age 50 or older) or unaffected (60 or&#xD;
             older);&#xD;
&#xD;
          -  participants in the proband's generation with an identified companion serving as an&#xD;
             informant;&#xD;
&#xD;
          -  participants who have capacity to consent or participants lacking capacity to consent&#xD;
             with a surrogate/proxy in place to provide consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  failure to identify an appropriate informant;&#xD;
&#xD;
          -  uncertainty of the clinical diagnosis of Alzheimer's disease or other related&#xD;
             disorder;&#xD;
&#xD;
          -  discovery of additional diagnosis that could account for the clinical manifestations;&#xD;
&#xD;
          -  unwillingness to participate;&#xD;
&#xD;
          -  failure to identify a living sibling with AD or other related disorder (except in the&#xD;
             cases of sporadic FTD and sporadic LBD);&#xD;
&#xD;
          -  participants lacking the capacity to consent who do not have a surrogate or proxy or&#xD;
             next of kin to provide consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard P. Mayeux, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Izri Martinez Soto</last_name>
    <phone>212-305-0865</phone>
    <email>imm2129@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dolly Reyes-Dumeyer</last_name>
    <email>dr2290@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Payne</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larry Deon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corey Woods</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Farber</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NCRAD at Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Farber</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Hanzel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Joanne Norton</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Norton</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Izri Martinez Soto</last_name>
      <phone>212-305-0865</phone>
      <email>imm2129@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Carolina State University</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27695</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takiyah Starks</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elise Weamer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Browning</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>September 16, 2022</last_update_submitted>
  <last_update_submitted_qc>September 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genetic testing</keyword>
  <keyword>Genetic influence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data is stored in a secured database at Columbia University and de-identified data will be sent to the National Cell Repository for Alzheimer's disease. DNA will be stored at the National Cell Repository for Alzheimer's disease (NCRAD) at Indiana University. In addition to the blood sample, year of birth, family history of dementia, and diagnosis will be sent to NCRAD. DNA and associated clinical and demographic data will be made available to qualified and approved researchers studying the genetics of AD, aging, and related disorders. If the participant agrees, his/her de-identified samples and data will be made available to investigators studying the genetics of any human disease. Identity of participants will not be shared with NCRAD or with any investigators.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>The data is currently available</ipd_time_frame>
    <ipd_access_criteria>When requesting samples to NCRAD the &quot;Master Agreement for Transfer of Materials to NCRAD&quot; and related Appendix A must be completed prior to the transfer of any samples. The Master Material Transfer Agreement (MTA) agreement is between the Institutions and is not Investigator specific. Therefore, if you think your Institution may already have a Master MTA in place with NCRAD.</ipd_access_criteria>
    <ipd_url>https://osp.od.nih.gov</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

